2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|September 7, 2018
Thermo Fisher Scientific to Acquire Advanced Bioprocessing Business from BD
Author(s)Pharmaceutical Technology Editors
Becton Dickinson’s (BD) Advanced Bioprocessing business will be integrated into Thermo Fisher's Life Sciences Solutions segment.
Advertisement
Thermo Fisher Scientific announced on Sept. 7, 2018 that it has signed a definitive agreement with Becton Dickinson (BD), a global medical technology company, under which Thermo Fisher will acquire BD's Advanced Bioprocessing business.
The business combines a technical services program with a variety of peptones that enhance cell-culture media formulations to improve yield and reduce variability in biopharmaceutical applications. Thermo Fisher reports that BD's Advanced Bioprocessing business has annualized revenue of approximately $100 million and will be integrated into Thermo Fisher's Life Sciences Solutions segment. The transaction is subject to customary closing conditions and is expected to close in early 2019.
"The addition of these new capabilities will complement our bioproduction offering and strengthen our ability to serve this rapidly growing market, from development to large-scale production," said Mark Stevenson, executive vice-president and chief operating officer of Thermo Fisher Scientific, in a company press release.
Source:
Advertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Advertisement
Advertisement